Abivax, a biotechnology company working to develop a functional cure for HIV as well as treatments for inflammatory/autoimmune diseases and cancer, appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member to the Company’s SAB. The changes have been made to support the transition from a discovery-focused biotechnology company to a biopharmaceutical development company.
Symcel appoints two new board members
AppointmentsSymcel has announced the appointment of two new board members; Erik Walldén and Stefan Löfås. Both will play a key role in the company’s corporate strategy to grow business in the research market and develop solutions for clinical diagnostics.
Improving models of chronic hepatitis
Latest NewsGerman and US researchers have designed a mouse model that exactly mimics the mechanisms of hepatitis infection in men.
GMO acreage growing globally
Latest NewsAgribiotech lobby group ISAAA reports that global GMO acreage has grown to 189.8 million hectares in 2017 -3% or 4.7 million hectares more than in 2016.
Chugai ends licence for PharmaMar’s lurbinectedin
Latest NewsRoche’s Japanese arm Chugai today returned all rights from a 2016 licence agreement on the RNA polymerase II blocker lurbinectedin to Spanish oncology specialist PharmaMar SA.
Microbial game-changers
BackgroundHow do novel technologies affect the world’s largest enzyme producer? At the GBS, European Biotechnology asked Thomas Videbaeck, PhD, COO and Executive VP Research, Innovation and Supply.
Inflammasome specialist NodThera Ltd raises €31.8m
Latest NewsSelvita spin-out NodThera Ltd raised £28 million (€31.8m) in a Series A financing round led by Sofinnova Partners and 5AM Ventures and co-financed by Epidarex Capital and F-Prime Capital Partners.
Dave Lemus joins Silence Therapeutics Board
AppointmentsSilence Therapeutics plc, a company active in the development of RNA therapeutics, has announced the appointment of Dave Lemus to its Board as Non-Executive Director.
Abivax Appoints Ian McGowan
AppointmentsAbivax, a biotechnology company working to develop a functional cure for HIV as well as treatments for inflammatory/autoimmune diseases and cancer, appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member to the Company’s SAB. The changes have been made to support the transition from a discovery-focused biotechnology company to a biopharmaceutical development company.
Researchers identify T cell guardians of the intestine
Latest NewsSpecial immune cells that protect the lining of the gut remain in a semi-active state, ready to fend off a pathogen at any moment, thanks to the composition of their mitochondrial membrane, a new study reveals.
Afatinib push back K-RAS-positive lung cancer
Latest NewsA team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.